The thymus is located behind the breastbone, close to many structures involved in thoracic cancers. Its primary function is to produce and educate T cells, a class of lymphocytes responsible for recognizing abnormal cells, coordinating immune responses, and eliminating infected or malignant targets. During childhood, the thymus is highly active, generating large numbers of naïve T cells capable of responding to unfamiliar antigens. The organ gradually becomes smaller and is replaced in part by fatty tissue with age, a process known as involution. For decades, this transformation led clinicians to assume that the adult thymus had little remaining importance. Recent studies from the same Mass General Brigham research group, however, have challenged that assumption by showing that many adults retain measurable thymic structure and function.

Those earlier investigations, published in Nature, used medical imaging and clinical data to examine how thymic condition relates to health across the adult lifespan. They reported associations between healthier thymuses and lower mortality, reduced risks of cardiovascular disease and cancer, and more favorable responses to immune checkpoint inhibitors. These drugs, which include several modern cancer immunotherapies, work by releasing inhibitory signals that prevent T cells from attacking tumors. Their effectiveness depends not only on the presence of T cells but also on the diversity, fitness, and ability of the immune system to generate new antitumor responses. A functioning thymus may contribute to this process by maintaining or replenishing the pool of naïve T cells available for activation.

The new study examined more than a thousand patients with locally advanced non-small cell lung cancer, a disease commonly treated with combinations of chemotherapy, radiation therapy, and immunotherapy. Radiation is directed at tumors and nearby lymph-node regions, but the thymus can lie within or near the treatment field because of its position in the upper chest. As a result, the organ may receive radiation even when it is not a therapeutic target. The researchers analyzed routine computed tomography scans with artificial-intelligence methods to estimate each patient’s thymic health before treatment. They also used treatment-planning information to quantify the radiation dose delivered to the thymus, allowing them to investigate whether baseline thymic condition and incidental exposure were associated with subsequent outcomes.

The analysis showed that patients with relatively preserved thymic health before radiotherapy generally had the most favorable clinical outcomes. Within this group, however, patients exposed to higher radiation doses to the thymus experienced significantly worse overall survival and were more likely to develop distant metastatic disease. Follow-up scans also indicated that thymic health declined after treatment among patients receiving greater thymic radiation exposure. The pattern is biologically plausible: radiation can damage rapidly dividing cells, alter tissue architecture, and promote inflammation or fibrosis. Injury to the thymus could reduce the production of naïve T cells or disrupt the specialized cellular environment required for T-cell maturation, potentially weakening immune surveillance at a time when patients are relying on both their own immune systems and immunotherapy.

The results were particularly notable among patients treated with durvalumab, an immune checkpoint inhibitor used after chemoradiation in certain cases of locally advanced lung cancer. Durvalumab targets the PD-L1 pathway, blocking a signal that tumors can use to suppress T-cell activity. In the study, patients with preserved thymic health appeared to be especially affected by the amount of radiation delivered to the thymus when they received durvalumab. This observation is consistent with the possibility that thymic function helps determine how effectively a patient can mount or sustain an immune response once checkpoint inhibition removes suppressive signals. It also raises the possibility that the same patients most capable of benefiting from immunotherapy could be particularly vulnerable to treatment-related damage to immune organs.

Artificial intelligence was central to the investigation because thymic structure can be difficult to evaluate consistently by eye, especially in adults whose thymus contains a mixture of soft tissue and fat. Imaging-based algorithms can process large numbers of CT scans and extract quantitative features that may be missed during routine clinical interpretation. In this study, the technology enabled the investigators to assess thymic condition before therapy and track changes afterward across a large patient population. Such methods could eventually support automated treatment planning, alerting radiation oncologists when a meaningful amount of dose is likely to reach a potentially functional thymus. However, imaging measurements remain indirect indicators of biological activity, and the study cannot determine precisely how changes seen on CT correspond to T-cell production or immune competence.

The investigators caution that the work is observational. Patients who received higher thymic radiation doses may have differed from other patients in ways that also influenced outcomes, including tumor location, disease extent, treatment geometry, overall health, or the radiation dose delivered to other organs. Although the researchers accounted for clinical and imaging information available in their analysis, unmeasured factors could still contribute to the associations. The results therefore should not be interpreted as evidence that radiation therapy should be reduced or withheld when it is needed to control a lung tumor. Radiation remains a foundational treatment for locally advanced disease, and protecting the thymus would have to be balanced against delivering an adequate dose to the cancer and involved lymph nodes.

Prospective studies will be required to determine whether deliberately limiting thymic radiation improves survival, reduces metastasis, or enhances responses to immunotherapy. Future trials could compare conventional radiation plans with thymus-sparing plans while measuring immune markers such as naïve T-cell counts, T-cell receptor diversity, circulating immune-cell populations, and changes in thymic imaging features. Researchers will also need to establish which adults retain enough thymic activity for protection to be clinically meaningful and whether the effect varies according to age, sex, baseline immune status, cancer subtype, or treatment regimen. If the findings are confirmed, the thymus could join the heart, lungs, and spinal cord as an organ whose dose is considered during thoracic radiation planning—not because it is the tumor, but because preserving the patient’s immune capacity may be part of achieving durable cancer control.

Subject of Research: The association between incidental thymic radiation exposure, thymic health, and clinical outcomes in patients with locally advanced non-small cell lung cancer.

Article Title: “Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC”

Web References: https://www.annalsofoncology.org/article/S0923-7534(26)00997-X/fulltext; https://www.nature.com/articles/s41586-026-10242-y; https://www.nature.com/articles/s41586-026-10243-x

References: Prudente, V. et al. “Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.” Annals of Oncology. DOI: 10.1016/j.annonc.2026.07.001

Keywords: Thymus, thymic health, radiation therapy, lung cancer, non-small cell lung cancer, immunotherapy, durvalumab, artificial intelligence, computed tomography, T cells, cancer outcomes, radiotherapy planning

The thymus is located behind the breastbone, in the upper central chest, close to the heart, lungs and major blood vessels. Its principal role is to produce and educate T cells, a group of white blood cells that identify infected or abnormal cells and coordinate immune attacks against them. During childhood, the thymus is highly active. After puberty, it gradually becomes smaller, and much of its functional tissue is replaced by fat in a process known as involution. Because of this visible decline, medical thinking for decades generally treated the adult thymus as biologically unimportant. Recent evidence, however, indicates that involution is highly variable and that some adults retain considerably more functional thymic tissue than others.

The study, published in Annals of Oncology, used artificial intelligence to estimate the condition of the thymus from routine computed tomography scans acquired before radiotherapy. Rather than relying only on the organ’s size, the researchers assessed several imaging features, including its shape, density and the balance between apparent functional tissue and fat. These measurements were combined into a thymic health score. A higher score represented a better-preserved thymus, while a lower score indicated extensive fatty replacement or structural changes consistent with reduced function or previous damage. The approach allowed the investigators to examine an immune organ that is not routinely measured during cancer care.

The researchers then mapped each patient’s radiotherapy treatment plan to determine how much radiation reached the thymus. In lung cancer treatment, the organ may receive an unintended dose because of its position in the centre of the chest. Radiotherapy is designed to destroy malignant cells by damaging their DNA, but tissues located near the target can also be exposed. Although modern planning systems can shape and direct radiation with increasing precision, the thymus is not generally designated as an organ that must be protected in adult patients. The investigators therefore asked whether incidental thymic irradiation might influence the long-term course of NSCLC.

The analysis included 460 patients from the randomised phase III RTOG-0617 trial, which compared different radiotherapy doses alongside carboplatin and paclitaxel-based chemoradiotherapy, with or without cetuximab. It also included 647 people treated in routine clinical settings across two additional cohorts. One group received platinum-based chemoradiotherapy between 2003 and 2014, while another was treated between 2017 and 2023 and subsequently received durvalumab, an immune checkpoint inhibitor that has become part of standard care for some patients with locally advanced NSCLC. Including patients treated before and after immunotherapy became routine allowed the researchers to explore whether the thymus might be particularly relevant when treatment depends on an active immune response.

Across all three patient groups, greater radiation exposure to the thymus was consistently associated with a higher likelihood of distant metastasis. The association was not uniform across the entire study population. It was concentrated among patients who had relatively healthy thymic tissue before treatment. In the RTOG-0617 trial, higher thymic radiation exposure in this subgroup was associated with a 29 percent increase in the risk of distant metastasis. The corresponding increase was 33 percent in the Harvard chemoradiotherapy cohort and 95 percent among patients who received chemoradiotherapy followed by durvalumab. The figures represent relative increases in risk, not proof that radiation directly caused each metastasis, and the study was observational in its central analysis.

The pattern raises a biological possibility: a functioning adult thymus may contribute to the supply and diversity of T cells available to detect and attack tumour cells, and radiation damage could weaken that reserve. The thymus does not act alone. Mature T cells circulate through the blood and lymphatic system, communicate with other immune cells and respond to signals released by tumours and treatments. A diverse T-cell population may improve the chances that at least some cells recognise abnormal tumour proteins. This could be especially important with durvalumab, which works by blocking an inhibitory pathway and releasing existing T cells to mount a stronger response. If radiation reduces the thymus’s ability to support T-cell production or diversity, immunotherapy may have a less effective immune system to activate.

Additional findings were consistent with this interpretation, although they did not establish it conclusively. Patients exposed to higher thymic radiation doses showed a greater decline in their thymic health score one year after treatment, suggesting that the organ may undergo measurable structural damage following irradiation. In a smaller subgroup for whom blood-count information was available, higher exposure also tended to coincide with lower lymphocyte counts. Lymphocytes include T cells, B cells and natural killer cells, so a total lymphocyte count cannot reveal precisely which immune populations changed. Nevertheless, the result provides a possible link between the radiation dose received by the thymus, alterations visible on imaging and changes in systemic immunity.

The researchers identified a potential practical response using radiotherapy planning methods that are already available. In treatment simulations, thymic exposure could often be reduced substantially without compromising the radiation delivered to the tumour or increasing doses to other critical organs. This does not mean that thymus-sparing is ready to become a universal clinical standard. The study included differences in patient selection, treatment technique and disease characteristics, and many participants were white, limiting certainty about how the findings apply across populations. The AI models were trained and tested on diverse imaging collections, but further validation will be needed across scanners, hospitals and countries. The analysis also used 35 gray (Gy) as an exploratory threshold separating lower and higher thymic radiation exposure; that value is not a validated clinical cut-off.

The authors say prospective studies should now test whether deliberately protecting the thymus improves immune recovery, treatment response, metastasis rates or survival. Such trials would need to compare carefully planned radiotherapy strategies while monitoring tumour control, blood-cell populations, T-cell diversity and the effects of immunotherapy. The results also reinforce a broader shift in oncology: protecting healthy organs may eventually include preserving immune tissues, not only the heart, lungs and spinal cord. If future research confirms that the association is causal, the thymus could become one of the first immune organs routinely considered during radiation planning for adults. For now, the findings offer a provocative warning that an organ once regarded as nearly obsolete may still influence the success of modern cancer treatment.

Subject of Research: People with non-small cell lung cancer

Article Title: Thymic radiation is associated with worse outcomes in patients with NSCLC

News Publication Date: 26-Aug-2026

Web References: https://doi.org/10.1016/j.annonc.2026.07.001

References: Prudente, V. et al. “Thymic radiation is associated with worse outcomes in patients with NSCLC.” Annals of Oncology. DOI: 10.1016/j.annonc.2026.07.001. Bernatz, S., Prudente, V., Pai, S. et al. “Thymic health consequences in adults.” Nature 652, 986–994 (2026). Bernatz, S., Prudente, V., Pai, S. et al. “Thymic health and immunotherapy outcomes in patients with cancer.” Nature 652, 995–1003 (2026).

Keywords: Thymus, immune system, non-small cell lung cancer, lung cancer, radiotherapy, radiation therapy, metastasis, immunotherapy, T cells, cancer treatment, artificial intelligence, thymic health

Immune checkpoint inhibitors work by blocking proteins such as PD-1, PD-L1, or CTLA-4, which cancer cells exploit to evade immune detection. By inhibiting these checkpoints, ICIs effectively ‘release the brakes’ on immune cells, enabling them to attack tumor cells more aggressively. Despite their efficacy, this mechanism can be a double-edged sword, eliciting inflammatory responses affecting organs including the lungs, colon, and liver. In clinical practice, the onset of irAEs introduces a complex clinical decision-making process, balancing toxicity management with continuing potentially life-saving therapy. The study led by Dr. Mark Awad and Federica Pecci meticulously explored this balance and the clinical trajectories following therapy cessation.

Drawing from a robust, multi-institutional cohort encompassing 2,794 NSCLC patients treated with ICIs as monotherapy or in combination with other treatments, approximately 10% who discontinued ICIs due to irAEs were evaluated for their subsequent clinical outcomes. Astonishingly, the median progression-free survival (PFS) following discontinuation was 12.7 months, while the overall survival (OS) extended to a median of 43.7 months. These findings illuminate the potential for a durable anticancer effect that persists beyond active treatment, a concept that challenges conventional paradigms requiring continuous therapy for disease control.

A notable aspect of the study was its stratification of patients based on treatment duration prior to discontinuation. Patients treated for less than three months before stopping immunotherapy had a median post-discontinuation PFS of 6.2 months, whereas those treated between three and six months, and more than six months had PFS durations of 13.9 and 25.8 months, respectively. Overall survival followed a similar trend, with median OS of 21.7 months, 42.7 months, and 86.9 months corresponding to these treatment intervals. These data suggest that longer exposure before discontinuation correlates with improved long-term outcomes, highlighting a possible dose-response effect even in the context of treatment cessation due to toxicity.

A deeper multivariable analysis identified several clinical and pathological factors associated with prolonged disease control after ICI discontinuation. High PD-L1 expression—a biomarker predicting responsiveness to ICIs—alongside achieving a complete or partial response to therapy, and longer duration of treatment before discontinuation, emerged as predictors of extended progression-free survival. Similarly, nonsquamous histology, robust tumor response, and extended treatment duration were linked with improved overall survival rates. These insights offer oncologists valuable parameters to identify patients who may safely discontinue immunotherapy without immediate risk of progression.

Intriguingly, the study also addressed the impact of managing irAEs with immunosuppressants such as corticosteroids. Historically, concern has prevailed that suppressing the immune system might diminish the efficacy of immunotherapy and compromise anticancer effects. However, the analysis revealed no significant difference in PFS or OS between patients who received steroids or other immunosuppressive agents and those who did not. This finding carries substantial clinical implications, reassuring providers and patients that necessary interventions for irAEs may not undermine long-term cancer control.

The implications of these findings extend beyond the clinical metrics, touching upon the quality of life and patient decision-making. Immune-related toxicities can considerably impair well-being, often forcing patients into a difficult crossroad where continuing treatment may not be feasible or desirable. The reassurance that durable responses can be sustained post-discontinuation empowers both clinicians and patients, facilitating more personalized treatment approaches that weigh toxicities against survival benefits in a nuanced fashion.

From a mechanistic standpoint, the persistently durable responses observed may be explained by the enduring activation of immunological memory even after cessation of checkpoint inhibition. Immune system priming and clonal expansion of tumor-reactive T cells might sustain antitumor activity, but this hypothesis requires further research. The study’s retrospective design and potential biases, such as the enrichment of long-term responders in longer treatment durations, are acknowledged limitations. Nonetheless, the authors employed landmark analyses and multivariable Cox models to reduce confounding factors and bolster the robustness of their conclusions.

Expert commentary by Dr. Pecci emphasized the study’s role as a clinical resource in guiding decisions about treatment discontinuation in the context of irAEs. The work aids clinicians in navigating the grey zones between necessary cessation for severe toxicity and cautiously continuing therapy in moderate cases. By identifying prognostic markers, physicians can tailor counseling and follow-up intensities, ultimately refining care in this complicated therapeutic landscape.

This research aligns with an evolving understanding of cancer immunotherapy, where the durability of responses transcends the duration of active treatment. It challenges the traditional dogma of indefinite therapy until progression or unacceptable toxicity, inviting a paradigm shift towards strategic treatment breaks when warranted. Future prospective studies are warranted to validate these findings and explore the molecular underpinnings of prolonged tumor control post-ICI discontinuation.

Funding from the National Institutes of Health supported this collaborative endeavor, with disclosures transparently reported. The lead investigator, Dr. Awad, noted extensive consulting relationships and institutional funding from multiple pharmaceutical entities involved in immunotherapy development, reflecting a well-connected research milieu. Federica Pecci declared no conflicts of interest, underpinning the integrity of the study’s findings.

This study, published in the authoritative journal Clinical Cancer Research, stands to influence treatment guidelines and patient management strategies in NSCLC immunotherapy. By elucidating the factors that predict extended survival and disease control after immunotherapy discontinuation due to irAEs, it empowers clinicians to make more informed, personalized decisions in a rapidly advancing field.

Subject of Research: Long-term outcomes and predictors of disease control in NSCLC patients after discontinuation of immune checkpoint inhibitors due to immune-related adverse events.

Article Title: Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer

News Publication Date: 18-Apr-2025

Web References:
https://doi.org/10.1158/1078-0432.CCR-24-2990

Keywords: Cancer immunotherapy, immune checkpoint inhibitors, non-small cell lung cancer, immune-related adverse events, disease progression, progression-free survival, overall survival, PD-L1 expression, immunosuppression, treatment discontinuation